1. Home
  2. SPRO vs PLRX Comparison

SPRO vs PLRX Comparison

Compare SPRO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$0.94

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Pliant Therapeutics Inc.

PLRX

Pliant Therapeutics Inc.

SELL

Current Price

$0.67

Market Cap

61.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SPRO
PLRX
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
61.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SPRO
PLRX
Price
$0.94
$0.67
Analyst Decision
Buy
Hold
Analyst Count
3
5
Target Price
★ $5.33
$2.50
AVG Volume (30 Days)
★ 320.0K
306.4K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
29.97
EPS
★ N/A
N/A
Revenue
★ $66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.24
N/A
52 Week Low
$0.95
$0.69
52 Week High
$3.08
$1.67

Technical Indicators

Market Signals
Indicator
SPRO
PLRX
Relative Strength Index (RSI) 34.32 19.20
Support Level N/A N/A
Resistance Level $1.27 $1.26
Average True Range (ATR) 0.06 0.04
MACD -0.01 -0.01
Stochastic Oscillator 3.18 0.00

Price Performance

Historical Comparison
SPRO
PLRX

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Share on Social Networks: